SVRA logo

SVRA
Savara Inc

22,686
Mkt Cap
$1.14B
Volume
310,769.00
52W High
$7.01
52W Low
$1.89
PE Ratio
-10.44
SVRA Fundamentals
Price
$5.55
Prev Close
$5.58
Open
$5.48
50D MA
$5.51
Beta
1.09
Avg. Volume
1.89M
EPS (Annual)
-$0.5344
P/B
5.62
Rev/Employee
$0.00
$1,135.21
Loading...
Loading...
News
all
press releases
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the EMA has validated the submission of the MOLBREEVI...
Business Wire·3d ago
News Placeholder
More News
News Placeholder
Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of "Moderate Buy" from Brokerages
Savara Inc. (NASDAQ:SVRA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the stock, MarketBeat Ratings reports...
MarketBeat·6d ago
News Placeholder
Savara (SVRA) to Release Earnings on Tuesday
Savara (NASDAQ:SVRA) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 31. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-31-savara-inc-stock...
MarketBeat·9d ago
News Placeholder
FY2026 Earnings Estimate for Savara Issued By HC Wainwright
Savara Inc. (NASDAQ:SVRA - Free Report) - Analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Savara in a research note issued to investors on Monday, March...
MarketBeat·15d ago
News Placeholder
Lifesci Capital Analysts Lift Earnings Estimates for Savara
Savara Inc. (NASDAQ:SVRA - Free Report) - Stock analysts at Lifesci Capital upped their Q2 2026 earnings per share estimates for Savara in a report released on Sunday, March 15th. Lifesci Capital...
MarketBeat·15d ago
News Placeholder
HC Wainwright Comments on Savara's Q1 Earnings (NASDAQ:SVRA)
Savara Inc. (NASDAQ:SVRA - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Savara in a research report issued on Monday, March 16th. HC Wainwright...
MarketBeat·16d ago
News Placeholder
VR Adviser Adds Over 1 Million Savara Shares
Key PointsVR Adviser Bought 1,059,332 shares of Savara...
Nasdaq News: Markets·18d ago
News Placeholder
Savara (NASDAQ:SVRA) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen downgraded shares of Savara from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·19d ago
News Placeholder
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending...
Business Wire·20d ago
News Placeholder
Rosalind Advisors Inc. Has $14.28 Million Position in Savara Inc. $SVRA
Rosalind Advisors Inc. raised its position in shares of Savara Inc. (NASDAQ:SVRA - Free Report) by 50.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and...
MarketBeat·20d ago
<
1
2
...
>

Latest SVRA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.